In a patient taking bupropion XL (Wellbutrin XL) 150 mg daily and escitalopram (Lexapro) 20 mg daily with poorly controlled depression and anxiety, should the next step be to increase the bupropion dose and/or add aripiprazole (Abilify) as augmentation?

Optimizing Treatment for Poorly Controlled Depression and Anxiety on Wellbutrin XL 150 mg and Lexapro 20 mg

The next best step is to add bupropion (increase Wellbutrin XL from 150 mg to 300 mg daily) rather than adding aripiprazole, as augmentation with bupropion demonstrates superior risk-benefit balance compared to aripiprazole augmentation, particularly when considering metabolic harms and tardive dyskinesia risk. 1

Evidence-Based Rationale

Dose Optimization of Bupropion First

• The current bupropion dose of 150 mg daily is subtherapeutic. The FDA-approved target dose for Wellbutrin XL is 300 mg/day given once daily in the morning, with the 150 mg dose serving as an initial starting dose only. 2

• Dose escalation to 300 mg can occur as early as day 4 of treatment if the initial 150 mg dose is adequately tolerated, with at least 24 hours between successive doses. 2

• If no clinical improvement occurs after several weeks at 300 mg/day, the dose can be increased to a maximum of 450 mg/day as a single daily dose, though full antidepressant effect may not be evident until 4 weeks or longer. 2

Why Bupropion Augmentation Over Aripiprazole

The most recent high-quality risk-benefit analysis (2025) provides compelling evidence:

• Bupropion augmentation (C-BUP) offers 20.7 depression-free day-equivalents (DFDs) net benefit over switching strategies in adults aged 18-64 years, equivalent to approximately 3 weeks faster remission of depressive symptoms. 1

• Aripiprazole augmentation (A-ARI) offers only 8.0 DFDs after accounting for tardive dyskinesia risk, and this benefit becomes negative (-22.8 DFDs) when metabolic harms are considered in overweight patients at baseline. 1

• Bupropion augmentation was preferred over aripiprazole in all age subgroups except ages 85-89 years with BMI <25. 1

Supporting Guideline Evidence

American College of Physicians guidelines (2023) demonstrate:

• No significant differences in efficacy between various augmentation strategies including bupropion and aripiprazole when added to SSRIs like citalopram (similar to escitalopram). 3

• Discontinuation due to adverse events was significantly lower with bupropion augmentation (12.5%) compared to buspirone augmentation (20.6%), suggesting better tolerability. 3

• One high risk-of-bias trial showed higher remission with aripiprazole versus bupropion augmentation (55.4% vs 34.0%), but this single study had methodological limitations. 3

Clinical Considerations for Anxiety

Bupropion's anxiogenic potential requires careful monitoring but should not preclude its use:

• Clinical trials suggest bupropion may reduce anxiety symptoms in depressed patients, showing comparable efficacy to SSRIs/SNRIs in mild to moderate anxiety. 4

• Initiate at lower doses and monitor for anxiogenic symptoms (agitation, nervousness, insomnia), which occur in 2-20% of patients depending on dose. 2

• Agitation (2-9%), anxiety (5-7%), and insomnia (11-20%) are dose-dependent side effects that can be managed by temporary dose reduction or short-term sedative-hypnotic use (usually not needed beyond first week). 2

• Avoid bedtime dosing to minimize insomnia. 2

Aripiprazole Considerations if Bupropion Optimization Fails

If bupropion dose optimization to 300-450 mg fails after 4-8 weeks:

• Aripiprazole augmentation at 2.5-10 mg/day can be considered, with evidence showing rapid improvement in some treatment-resistant cases. 5

• Monitor closely for metabolic side effects (weight gain), extrapyramidal symptoms, and tardive dyskinesia risk, particularly in overweight patients. 1

• Aripiprazole may have advantages for cognitive function enhancement (executive function, continuous attention) when combined with escitalopram. 6

Recommended Treatment Algorithm

1. Increase Wellbutrin XL from 150 mg to 300 mg daily (given once in the morning). 2

2. Monitor for agitation, anxiety, and insomnia during dose escalation, particularly in the first 1-2 weeks. 2

3. Assess response after 4 weeks at 300 mg daily. 2

4. If inadequate response, consider increasing to 450 mg daily (maximum dose). 2

5. If still inadequate after 4-8 weeks at optimized bupropion dose, then consider aripiprazole augmentation starting at 2.5-5 mg daily. 1, 5

Important Caveats

• In patients aged 85+ years, fall risk from bupropion augmentation may offset benefits, making aripiprazole potentially preferable in this specific population. 1

• Patients with severe hepatic cirrhosis should not exceed 150 mg every other day of Wellbutrin XL. 2

• Pretreatment anxious depression may predispose patients to more frequent CNS side effects (nervousness, agitation) with escitalopram, which should be monitored. 7